| 词条 | ProSavin |
| 释义 |
It is manufactured by Oxford BioMedica, who plan to start European Phase I and Phase II clinical trials in 2007. Animal trials have been a success, with dopamine levels restored without the side effects associated with other current treatments for Parkinson's,[2] in particular, without the jerky involuntary movements associated with current drugs.[3] Mechanism of ActionProsavin uses Oxford BioMedica's Lentivector delivery system to transfer three genes, aromatic amino acid dopa decarboxylase, tyrosine hydroxylase and GTP-cyclohydrolase 1, to the striatum in the brain, reprogramming transduced cells to secrete dopamine.[4] https://archive.is/20140316165827/http://www.oxfordbiomedica.co.uk/prosavin-r/ See also
References1. ^Oxford BioMedica. [https://web.archive.org/web/20040512074154/http://www.oxfordbiomedica.co.uk/prosavin.htm Drug Information Page]. Retrieved on March 29, 2007. 2. ^Daily Telegraph. [https://www.telegraph.co.uk/money/main.jhtml?xml=/money/2007/03/29/cxquest29.xml Investor Information]. Retrieved on March 29, 2007. 3. ^{{cite web|url=https://www.reuters.com/article/scienceNews/idUSTRE59D4DL20091014|publisher=Reuters|title=Long-term monkey tests back Oxford's gene therapy|author=Ben Hirschler|date=2009-10-14|accessdate=2009-10-14}} 4. ^Oxford BioMedica . Drug Advanced Information Page{{dead link|date=April 2018 |bot=InternetArchiveBot |fix-attempted=yes }}. Retrieved on April 5, 2007. 2 : Drugs acting on the nervous system|Virotherapy |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。